Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year 2020 Concept
Program Announcement With Special Receipt, Referral, and/or Review Considerations—proposed FY 2020 initiative
Contact: Frosso Voulgaropoulou
Objective: The purpose of this initiative is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, enable early detection and molecular diagnosis, and support developing strategies to treat and eventually cure these disorders. Studies using human samples are encouraged if they are within the research objectives and scope of the initiative. Studies using human samples obtained from ongoing clinical trials supported outside this initiative will also be accepted. Investigators are encouraged to make use of clinical data and samples maintained in primary immunodeficiency registries, consortium databases, and repositories including, but not limited to, the registry and/or repository available through the United States Immune Deficiency Network at USIDNET, the Severe Chronic Neutropenia International Registry at SCNIR, and the Primary Immune Deficiency Treatment Consortium at PIDTC, if these resources will be helpful.
Typical grants propose pilot and feasibility studies; secondary analyses of existing data; small, self-contained research projects; development of research methodology; or development of new research methodology. Preliminary data are not required for the R03 grant mechanism, but expertise in and a plan for applying immunologic, genetic, biochemical, and molecular biologic principles to primary immunodeficiency disease research is essential for success in review. Successful R21 applications typically have considerable preliminary data that strongly support a two-year research plan.
Description: This funding opportunity announcement (FOA) will solicit standard R03 and R21 applications with primary immunodeficiency disease-specific objectives and scope but no special instructions or review criteria. No changes from the currently active FOAs are proposed.
Request for Applications—proposed FY 2021 initiative
Contact: Leighton Thomas
Objective: To enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans, and to develop improved tolerogenic interventions for preventing and treating immune system-mediated diseases (including transplant rejection, autoimmune diseases, and asthma and allergic diseases).
Description: This initiative will renew NIAID's successful Immune Tolerance Network (ITN), a consortium of basic and clinical scientists that 1) develops a scientific agenda for clinical trials and mechanistic studies of various approaches to tolerance induction, 2) designs and conducts clinical trials at all phases to determine the feasibility, safety, toxicity, and efficacy of tolerogenic intervention strategies for multiple immune system diseases, 3) designs and conducts research to delineate the underlying mechanisms of immune tolerance in conjunction with clinical trials undertaken by the ITN as well as research projects sponsored by other federal and private sector organizations and companies, and 4) develops, tests, and validates assays to measure the induction, maintenance, and loss of immune tolerance in humans. For this initiative, tolerance is broadly defined as a clinical phenotype characterized by selective elimination of pathogenic immune responses to relevant antigens (e.g., alloantigens, autoantigens, or allergens) with preservation of protective immunity, with no or minimal ongoing immunologic intervention. Approaches may target antigen-specific receptors, molecules of the co-stimulation pathways, homing molecules, or other relevant approaches, and may use any of a variety of agents including antigen, peptides, altered peptides, monoclonal antibody blockade, cytokines, cellular therapies, molecularly engineered cells or tissues, DNA vectors, or other relevant molecules.